Pfizer will start testing its coronavirus vaccine on children as young as 12, a crucial step to bringing the shot to more people



a woman in glasses looking at the camera: Steve Parsons-WPA Pool/Getty Images


© Steve Parsons-WPA Pool/Getty Images
Steve Parsons-WPA Pool/Getty Images

  • Pfizer is expanding its massive coronavirus vaccine clinical trial, opening the study to include children as young as 12.
  • The company is poised to become the first major drugmaker to start testing a COVID-19 shot in kids in a large-scale study.
  • The New York pharma giant said it got permission to boost the study’s overall size to as many as 48,400 volunteers.
  • Pfizer broadened the study last month to include 16- and 17-year-olds as well as people with HIV, hepatitis B, or hepatitis C. 
  • While early clinical results were promising, it remains to be seen if Pfizer’s vaccine — or any other experimental shot — can prevent COVID-19.
  • Pfizer CEO Albert Bourla has said he expects data from this study before the end of October. 
  • Visit Business Insider’s homepage for more stories.

Pfizer is setting plans to make its coronavirus vaccine

Read More

Clinical Trials & the COVID-19 Vaccine

Findings Uncover More than 1 in 3 Americans Don’t Trust How Quickly COVID-19 Vaccine Clinical Trials Are Moving

LONDON, Oct. 01, 2020, the global business intelligence provider for the biopharma industry, today released its “Pulse Report: Clinical Trials & the COVID-19 Vaccine” study which uncovered American sentiment and confidence around COVID-19 vaccine clinical trials. According to the data, more than 1 in 3 (35%) Americans don’t trust how quickly the COVID-19 vaccine clinical trials are moving, and more than 1 in 5 (23%) don’t think pharmaceutical companies have consumers’ best interests at mind during COVID-19 vaccine clinical trials.

The study conducted with third-party research firm YouGov,found that while Americans are wary of the current vaccine development process, they are paying attention to it with 22% saying they regularly look for updates on COVID-19 vaccine clinical trials. As such, developers must prioritize further education and transparency around the process.

Read More

Informa Business Intelligence: Informa Pharma Intelligence Launches New Pulse Report: Clinical Trials & the COVID-19 Vaccine

Findings Uncover More than 1 in 3 Americans Don’t Trust How Quickly COVID-19
Vaccine Clinical Trials Are Moving

LONDON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence, the
global business intelligence provider for the biopharma industry, today
released its “Pulse Report: Clinical Trials & the COVID-19 Vaccine” study
which uncovered American sentiment and confidence around COVID-19 vaccine
clinical trials. According to the data, more than 1 in 3 (35%) Americans don’t
trust how quickly the COVID-19 vaccine clinical trials are moving, and more
than 1 in 5 (23%) don’t think pharmaceutical companies have consumers’ best
interests at mind during COVID-19 vaccine clinical trials.

The study conducted with third-party research firm YouGov, found that while
Americans are wary of the current vaccine development process, they are paying
attention to it with 22% saying they regularly look for updates on COVID-19
vaccine clinical trials. As such, developers must prioritize further education
Read More

India declines proposal to test Sputnik-V COVID-19 vaccine in large study

Oct 7 (Reuters) – India’s drug regulator has knocked back a proposal from Dr Reddy’s Laboratories Ltd to conduct a large study in the country to evaluate Russia’s Sputnik-V COVID-19 vaccine and has asked it to first test the vaccine in a smaller trial.

The recommendations here by an expert panel of the Central Drugs Standard Control Organisation (CDSCO) noted that safety and immunogenicity data from early-stage studies being conducted overseas is small, with no inputs available on Indian participants.

India’s move comes as a setback for Russia’s plan to roll-out the vaccine even before full trials show how well it works, while pushing back its efforts to win approval for the vaccine in the country that leads the world on average number of new infections.

India is expected to overtake the United States over the next several weeks as the country with the world’s largest number of cases.

The

Read More